
Phoenix-based private investment firm Pivotal Group has acquired Precision Science, a local contract manufacturer that's been producing animal health pharmaceuticals, medicated feed additives and nutritional supplements since 1989. The deal, announced Tuesday, marks Pivotal Group's first move into the animal health space, and it comes as the company's North Phoenix manufacturing facility sits roughly two-thirds complete.
According to the acquisition announcement distributed via PR Newswire, Pivotal Group has already invested additional capital and resources in Precision Science since the deal closed, aiming to boost manufacturing capacity and strengthen the technology, personnel and infrastructure that support its clients. As citybiz reported, the acquisition represents a diversification of Pivotal Group's portfolio into animal health and pharmaceutical contract manufacturing, a sector the firm sees as ripe for expansion.
Precision Science operates an FDA-registered facility backed by an in-house laboratory and established quality management systems, per the announcement. The company has built established customer relationships and specialized production expertise over nearly four decades in business, serving global animal health companies, supplement brands and businesses in the veterinary and animal care markets.
A Nearly Complete Plant Signals Bigger Ambitions
The centerpiece of the expansion is a highly automated facility under construction in North Phoenix. The announcement describes it as 130,000 square feet and already two-thirds complete, while a separate 2024 report on the project from Kidder Mathews put the leased space at 130,030 square feet; the discrepancy between those two figures isn't addressed in either account. No completion date for the facility has been disclosed.
Once finished, the new plant will operate alongside Precision Science's existing manufacturing infrastructure, adding three production lines and expanding the company's capabilities into liquid formulations. The facility is also expected to increase analytical testing and product development capacity, plus add storage, logistics and distribution space, according to the announcement.
Precision Science said the expanded platform will create opportunities to hire additional manufacturing and leadership talent in Phoenix, though the 2026 announcement doesn't specify a number or timeline. That's a change from earlier reporting: the 2024 Kidder Mathews account on the lease said Precision Science planned to hire 80 to 100 additional employees to support operations at the new facility.
Executives Frame the Deal as a Platform Play
Precision Science CEO Bryan Vincent said the acquisition will provide resources for the company's next development phase, and that clients want the firm to anticipate shifts in animal health and invest in the capabilities needed to meet them. Pivotal Group founder and CEO Francis Najafi said the deal offers an opportunity to build out an animal health platform starting with supplements and pharmaceuticals, framing Precision Science as a chance to establish a larger manufacturing business in a market the firm views as growing.
Pivotal Group describes itself as a firm focused on acquiring and developing businesses with established market positions and long-term growth potential. Its past investments include technology companies Network Solutions, Global Capacity, Global Meet and MegaPath, and the firm also owns and operates Promontory, a luxury mountain community in Park City, Utah.
The Deal Lands Amid a Pet Care M&A Boom
The acquisition arrives during a notably active stretch for pet care dealmaking. Pet care mergers and acquisitions climbed 22.4% year over year to 60 announced or completed transactions in 2026, according to data from Capstone Partners cited by Petfood Industry. Private-equity activity in the sector rose even faster, up 56.3% year over year, with investors concentrating on health, wellness and services.
Capstone's analysis pointed to science-backed premium health and wellness products — those built around clinical-grade ingredients — as the primary driver of buyer interest in the category. The trend has already produced some sizable transactions elsewhere in the industry: Chewy acquired Modern Animal in April 2026 for $400 million, or 3.2 times revenue, and bought SmartPak Equine in October 2025 for $175 million, or 2.2 times sales, per the same Petfood Industry report.
Financial terms of the Pivotal Group-Precision Science deal were not disclosed, and neither Precision Science's annual revenue nor its employee count was made public in the announcement. The acquisition price itself also remains undisclosed. What is clear is that Pivotal Group is positioning the newly acquired company, paired with its still-rising North Phoenix facility, to chase growth in animal health pharmaceuticals and supplements as the broader sector draws fresh investor attention.









